Astellas and graduate school of medicine / faculty of medicine, osaka university enter into research collaboration to develop pluripotent stem cell-derived cartilage organoid cell therapy

- collaborative research on innovative cartilage organoid cell therapy for intervertebral disc degenerative disease using astellas' universal donor cell technology - tokyo and osaka, japan , july 22, 2024 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas") and graduate school of medicine / faculty of medicine, osaka university (president: shojiro nishio "osaka university") today announced that astellas institute for regenerative medicine (a wholly owned subsidiary of astellas, "airm"), universal cells (a wholly owned subsidiary of astellas) and osaka university have entered into a research collaboration to develop innovative pluripotent stem cell*1-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease*2. universal cells holds the rights to universal donor cell (udc) technology to create cell therapy products from pluripotent stem cells that have reduced risk of immune rejection by genetically modifying human leukocyte antigen (hla) using gene editing technology.
UVV Ratings Summary
UVV Quant Ranking